绿叶制药(02186)五款新产品成功纳入2025年国家医保药品目录或商保创新药目录

智通财经
Dec 07, 2025

智通财经APP讯,绿叶制药(02186)发布公告,集团共有五款新产品成功纳入由国家医疗保障局发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新药品目录(2025年)》(商保创新药目录)。

该五款新产品包括:米美欣®(羟考酮纳洛酮缓释片)、瑞百莱®(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国家医保药品目录;赞必佳®(注射用芦比替定)成功入选商保创新药目录;百拓维®(注射用戈舍瑞林微球)、瑞可妥®(注射用利培酮微球(Ⅱ))顺利续约,继续被纳入国家医保药品目录。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10